Analyst Ratings for Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter, with a majority being bullish. The average price target for the company is $65.6, representing a 23.83% decrease from the previous average price target of $86.12.

September 14, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The majority of analysts are bullish on Apellis Pharmaceuticals, but the average price target has decreased by 23.83% to $65.6.
The majority of analysts are bullish on Apellis Pharmaceuticals, indicating a positive sentiment towards the company. However, the decrease in the average price target suggests that analysts expect the stock price to decrease in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100